生物相似契約製造市場規模、佔有率和成長分析：按分子類型、服務類型、應用和地區分類－2026-2033年產業預測

2024 年全球生物相似契約製造市場價值為 58.2 億美元，預計到 2025 年將成長至 66.1 億美元，到 2033 年將成長至 184.2 億美元，在預測期（2026-2033 年）內複合年成長率為 13.62%。

生物相似契約製造市場正經歷顯著成長，主要促進因素是生技藥品製劑專利專利到期以及對具成本效益治療方案日益成長的需求。該市場涵蓋專注於生物類似單株抗體和重組蛋白的合約開發和生產機構 (CDMO)，為降低醫療成本和提高藥物可近性提供了途徑。生物相似藥監管政策的不斷完善推動了該市場從利基市場轉向大規模市場的轉變。該行業成功的關鍵要素包括可擴展的生產能力和技術專長，這促使主要企業投資於創新生產方法，例如一次性系統和模組化設施。這些策略投資能夠實現高效的規模化生產、降低污染風險並提高價格競爭力，從而鼓勵發起公司與成熟的契約製造建立合作關係。

全球生物相似藥契約製造市場的促進因素

全球生物相似藥契約製造市場的主要促進因素之一是慢性病盛行率的上升和人口老化，這推動了對生物製藥的需求。隨著全球醫療保健系統面臨著在降低成本的同時提高基本藥物可及性的壓力，生物相似藥正成為昂貴的原廠生物製藥的一種經濟有效的替代方案。這一趨勢促使製藥公司利用契約製造組織 (CMO) 來高效生產生物類似藥，最佳化產能，同時確保符合監管標準。此外，生物製造製程的技術進步正在提高生物相似藥的可擴展性和可靠性，進一步加速市場成長。

全球生物相似契約製造市場的限制因素

全球生物相似藥契約製造市場的主要限制因素之一是嚴格的法規結構，該框架規範生物類似藥的核准和商業化。這些法規要求進行大規模臨床試驗以證明其安全性和有效性，導致成本增加和上市時間延長。此外，生物相似藥生產的複雜性，包括對先進技術和專業知識的需求，阻礙了中小企業進入市場，並限制了整體競爭。另外，不同地區的監管標準差異進一步加劇了這種情況，使得製造商難以在有效控制生產成本的同時，有效遵守法規。

全球生物相似契約製造市場趨勢

全球生物相似藥契約製造市場正呈現向策略合作開發夥伴關係發展的顯著趨勢。這些夥伴關係涉及製造商與研發公司合作，透過風險共擔和策略協同加速生物相似藥的市場准入。這種協同效應結合了發起方在法規遵循方面的專業知識及其技術生產能力，從而促進了高效的技術轉移和精簡的服務交付。此外，對靈活智慧財產權框架的重視增強了供應的確定性並最佳化了運轉率。這類策略聯盟不僅擴大了生物相似藥的市場進入，也增強了研發公司的競爭力，體現了一種在瞬息萬變的市場環境中日益受到支持的合作模式。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球生物相似契約製造市場規模：依分子類型分類

• 單株抗體（mAbs）
• 促紅血球生成素
• 顆粒細胞增生因子（G-CSF）
• 胰島素
• 其他

全球生物相似契約製造市場規模：按服務類型分類

• 製程開發
• 分析與發展
• 生產製造（臨床/商業）
• 灌裝和精加工服務

全球生物相似契約製造市場規模：按應用領域分類

• 腫瘤學
• 自體免疫
• 糖尿病
• 其他

全球生物相似契約製造市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lonza Group
• Boehringer Ingelheim
• Samsung Biologics
• WuXi Biologics
• Fujifilm Diosynth Biotechnologies
• Patheon（Thermo Fisher）
• AGC Biologics
• Catalent Inc.
• Rentschler Biopharma
• Abzena Ltd.
• Cobra Biologics
• Binex Co.
• Mabion SA
• Alteogen
• Celltrion

結論與建議

Global Biosimilar Contract Manufacturing Market size was valued at USD 5.82 Billion in 2024 and is poised to grow from USD 6.61 Billion in 2025 to USD 18.42 Billion by 2033, growing at a CAGR of 13.62% during the forecast period (2026-2033).

The biosimilar contract manufacturing market is witnessing significant growth, driven primarily by the expiration of biologic patents and the rising demand for cost-effective therapy solutions. This market includes contract development and manufacturing organizations that focus on biosimilar monoclonal antibodies and recombinant proteins, providing a pathway to reduce healthcare costs and enhance drug accessibility. The transition from a niche sector to a substantial market is attributed to evolving regulations that support biosimilars. Key factors for success in this industry include scalable capacity and technical expertise, leading companies to invest in innovative production methods like single-use systems and modular facilities. This strategic investment results in efficient scale-up processes, lower contamination risks, and competitive pricing, enticing sponsors to partner with established contract manufacturing organizations.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biosimilar Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biosimilar Contract Manufacturing Market Segments Analysis

Global biosimilar contract manufacturing market is segmented by molecule type, service type, application and region. Based on molecule type, the market is segmented into Monoclonal Antibodies (mAbs), Erythropoietin, Granulocyte Colony-Stimulating Factor (G-CSF), Insulin and Others. Based on service type, the market is segmented into Process Development, Analytical Development, Manufacturing (Clinical & Commercial) and Fill-Finish Services. Based on application, the market is segmented into Oncology, Autoimmune, Diabetes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biosimilar Contract Manufacturing Market

One of the key market drivers for the Global Biosimilar Contract Manufacturing Market is the increasing prevalence of chronic diseases and the growing aging population, which are fueling the demand for biologics. As healthcare systems worldwide face pressure to contain costs while improving access to essential medications, biosimilars emerge as a cost-effective alternative to expensive reference biologics. This trend encourages pharmaceutical companies to leverage contract manufacturing organizations (CMOs) to efficiently produce biosimilars, ensuring compliance with regulatory standards while optimizing production capabilities. Additionally, technological advancements in biomanufacturing processes enhance the scalability and reliability of biosimilars, further accelerating market growth.

Restraints in the Global Biosimilar Contract Manufacturing Market

One key market restraint for the global biosimilar contract manufacturing market is the stringent regulatory framework governing the approval and commercialization of biosimilars. These regulations require extensive clinical trials to demonstrate safety and efficacy, leading to increased costs and longer timeframes for market entry. Furthermore, the complexities involved in manufacturing biosimilars, including the need for advanced technology and highly specialized expertise, can deter smaller companies from entering the market, limiting overall competition. Additionally, varying regulatory standards across different regions further complicate the landscape, making it challenging for manufacturers to navigate compliance effectively while also managing production costs.

Market Trends of the Global Biosimilar Contract Manufacturing Market

The Global Biosimilar Contract Manufacturing market is witnessing a significant trend towards strategic co-development partnerships, where manufacturers collaborate with developers to expedite biosimilar market entry through shared risks and aligned strategies. This synergy combines the sponsor's expertise in navigating regulatory landscapes with technical manufacturing capabilities, facilitating efficient technology transfers and streamlined service delivery. Additionally, an emphasis on flexible intellectual property frameworks enhances supply assurances and optimizes capacity utilization. Such strategic alliances not only broaden market access for biosimilars but also strengthen the competitive positioning of developers, reflecting a collaborative approach that is increasingly favored in this dynamic market landscape.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Biosimilar Contract Manufacturing Market Size by Molecule Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies (mAbs)
• Erythropoietin
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Insulin
• Others

Global Biosimilar Contract Manufacturing Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Process Development
• Analytical Development
• Manufacturing (Clinical & Commercial)
• Fill-Finish Services

Global Biosimilar Contract Manufacturing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Autoimmune
• Diabetes
• Others

Global Biosimilar Contract Manufacturing Market Size & CAGR (2026-2033)

• North America (Molecule Type, Service Type, Application)
  • US
  • Canada
• Europe (Molecule Type, Service Type, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule Type, Service Type, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule Type, Service Type, Application)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule Type, Service Type, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Patheon (Thermo Fisher)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rentschler Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abzena Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cobra Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Binex Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mabion SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alteogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations